Administration of 3,5-diiodothyronine (3,5-T2) Causes Central Hypothyroidism and Stimulates Thyroid-sensitive Tissues
Overview
Authors
Affiliations
In general, 3,5-diiodothyronine (3,5-T2) increases the resting metabolic rate and oxygen consumption, exerting short-term beneficial metabolic effects on rats subjected to a high-fat diet. Our aim was to evaluate the effects of chronic 3,5-T2 administration on the hypothalamus-pituitary-thyroid axis, body mass gain, adipose tissue mass, and body oxygen consumption in Wistar rats from 3 to 6 months of age. The rats were treated daily with 3,5-T2 (25, 50, or 75 μg/100 g body weight, s.c.) for 90 days between the ages of 3 and 6 months. The administration of 3,5-T2 suppressed thyroid function, reducing not only thyroid iodide uptake but also thyroperoxidase, NADPH oxidase 4 (NOX4), and thyroid type 1 iodothyronine deiodinase (D1 (DIO1)) activities and expression levels, whereas the expression of the TSH receptor and dual oxidase (DUOX) were increased. Serum TSH, 3,3',5-triiodothyronine, and thyroxine were reduced in a 3,5-T2 dose-dependent manner, whereas oxygen consumption increased in these animals, indicating the direct action of 3,5-T2 on this physiological variable. Type 2 deiodinase activity increased in both the hypothalamus and the pituitary, and D1 activities in the liver and kidney were also increased in groups treated with 3,5-T2. Moreover, after 3 months of 3,5-T2 administration, body mass and retroperitoneal fat pad mass were significantly reduced, whereas the heart rate and mass were unchanged. Thus, 3,5-T2 acts as a direct stimulator of energy expenditure and reduces body mass gain; however, TSH suppression may develop secondary to 3,5-T2 administration.
Giacco A, Petito G, Silvestri E, Scopigno N, Vigliotti M, Mercurio G Front Endocrinol (Lausanne). 2024; 15:1432819.
PMID: 39301315 PMC: 11410700. DOI: 10.3389/fendo.2024.1432819.
Petito G, Cioffi F, Magnacca N, de Lange P, Senese R, Lanni A Pharmaceuticals (Basel). 2023; 16(4).
PMID: 37111329 PMC: 10146771. DOI: 10.3390/ph16040572.
Incerpi S, Gionfra F, De Luca R, Candelotti E, De Vito P, Percario Z Front Endocrinol (Lausanne). 2022; 13:961744.
PMID: 36213288 PMC: 9540375. DOI: 10.3389/fendo.2022.961744.
Sane R, Wirth E, Kohrle J Metabolites. 2022; 12(7).
PMID: 35888706 PMC: 9322486. DOI: 10.3390/metabo12070582.
Petito G, Cioffi F, Silvestri E, De Matteis R, Lattanzi D, de Lange P Front Endocrinol (Lausanne). 2021; 12:703170.
PMID: 34322094 PMC: 8312549. DOI: 10.3389/fendo.2021.703170.